Protego Biopharma
SAN DIEGO, CA · Biotechnology · 26 employees
Protego Bio is a clinical-stage company focused on the discovery and development of first-in-class small-molecule therapeutics that aim to reprogram protein folding for the treatment of various diseases. We are exploring monogenetic protein misfolding diseases that cause myopathy, cardiomyopathy, stroke, renal disease, retinal diseases, channelopathies, and various degenerative diseases. Our appro
Funding history
- Venture - Series Unknown — $32.9M — Dec 2025
- Series B — $130.0M — Dec 2025
- Venture - Series Unknown — $51.0M — Oct 2021
- Venture - Series Unknown — $1.0M — Dec 2019
Recent signals
- Jun 08, 2026: Protego Biopharma Appoints Jae B. Kim as Chief Medical Officer
- Dec 03, 2025: Raised $32.9M in Venture - Series Unknown
- Dec 01, 2025: Raised $130.0M in Series B
- Oct 28, 2021: Raised $51.0M in Venture - Series Unknown
- Dec 17, 2019: Raised $1.0M in Venture - Series Unknown
See plans & pricing → Track Protego Biopharma’s funding, hiring, and signals — with verified contacts — on Fundz.